Vir Biotechnology

Yahoo Finance • 7 days ago

Why a Biotech Fund Opened a New $6 Million Position in Vir Amid a 99% Stock Rally

Superstring Capital Management disclosed a new position in Vir Biotechnology(NASDAQ:VIR), acquiring 730,548 shares in the first quarter. The estimated transaction value was $5.82 million based on quarterly average pricing. What happened... Full story

Yahoo Finance • 12 days ago

Vir Biotechnology Stock Has Nearly Doubled in a Year. One Major Holder Just Trimmed $17 Million

SB Investment Advisers (UK) Ltd reported a sale of 2,168,884 shares of Vir Biotechnology(NASDAQ:VIR) in its May 15, 2026, SEC filing, an estimated $17.28 million trade based on quarterly average pricing. What happened According to an SEC... Full story

Yahoo Finance • 13 days ago

Vir Biotechnology Stock Has Doubled This Past Year. One Fund Just Bought 1.2 Million Shares

On May 15, 2026, Boxer Capital Management disclosed a purchase of 1,241,000 Vir Biotechnology(NASDAQ:VIR) shares, an estimated $9.89 million trade based on quarterly average pricing. What happened According to a Securities and Exchange C... Full story

Yahoo Finance • 16 days ago

"Cold" Solid Tumors Become the Proving Ground for a New Generation of Engager and Immune-Priming Therapies

Issued on behalf of GT Biopharma, Inc. After more than $1.7 billion in dealmaking and a string of Phase 1 starts in 2026, prostate, pancreatic, and other historically immunotherapy-resistant solid tumors are suddenly among the busiest bat... Full story

Yahoo Finance • 21 days ago

Vir Biotechnology's Chairman of the Board Sold 22,000 Company Shares. Here's What That Means for Investors.

Key Points Vicki Sato sold 22,000 shares on May 1, 2026, generating a transaction value of ~$221,000 at around $10.05 per share. This trade represented 2% of Sato's direct holdings, reducing her position from 1.10 million to 1,078,391 sha... Full story

Yahoo Finance • last month

Vir Biotechnology (VIR) Posts 80.98% Year-To-Date Growth

Vir Biotechnology, Inc. (NASDAQ:VIR) is one of the 10 Best Small-Cap Biotech Stocks According to Hedge Funds. The stock’s price grew 91.62% from a year ago, while it registered an 80.98% increase year-to-date. On April 16, Vir Biotechnolog... Full story

Yahoo Finance • 2 months ago

Vir Biotechnology (VIR) CEO Sells 73,000 Shares for $664,000

Key Points 72,559 shares were sold for a total transaction value of ~$664,000 on April 6, 2026. This sale represented 6.76% of De Backer's total holdings at the time of the transaction. The transaction involved only direct holdings, with... Full story

Yahoo Finance • 2 months ago

Vir Biotechnology (VIR) Leading with Its BiTEs Therapy

Jacob Funds, a mutual fund company, released its first-quarter 2026 investor letter. A copy of the letter can be downloaded here. The Fund started the year optimistically, expecting fiscal and monetary policies to boost an economy showing... Full story

Yahoo Finance • 3 months ago

TheStreet Pro: Four Stocks that Will Win Despite “Irrational Panic” over AI

The big news this week is AI may not be the economic savior that companies were hoping for. Sure, AI will help cut costs and make companies more profitable. At least, initially. What happens next is the big question. Claim 50% Off TipRank... Full story

Yahoo Finance • 3 months ago

Vir Biotechnology launches $200M public stock offering

* Vir Biotechnology (VIR [https://seekingalpha.com/symbol/VIR]) announced [https://seekingalpha.com/pr/20412007-vir-biotechnology-announces-proposed-public-offering-of-common-stock] plans to offer $200M of its common stock in an underwri... Full story

Yahoo Finance • 3 months ago

Stocks making the biggest moves midday: IBM, AMD, Dillard's, Novo Nordisk, Keysight Technologies & more

Check out the companies making headlines in midday trading: Dillard's — Shares fell 7% after the department store posted weaker-than-expected revenue in the holiday quarter. Fourth-quarter revenue came in at $1.99 billion, while analysts p... Full story

Yahoo Finance • 3 months ago

Anthropic expands Claude AI chatbot, Keurig Dr Pepper's Q4 beat

Market Catalysts Host Julie Hyman and Yahoo Finance Markets and Data Editor Jared Blikre tracks several of the day's top trending stock tickers, including Anthropic (ANTH.PVT) announcing new tools for its Claude AI chatbot, Keurig Dr Peppe... Full story

Yahoo Finance • 3 months ago

Vir Biotech Catapults On Its $1.71 Billion Deal With Astellas

Vir stock catapulted Tuesday after the small biotech company smashed fourth-quarter sales views and signed a deal with Astellas Pharma. Continue Reading... Full story

Yahoo Finance • 3 months ago

Vir Biotechnology (VIR) Earnings Call Transcript

Image source: The Motley Fool. DATE Monday, Feb. 23, 2026 at 5:30 p.m. ET CALL PARTICIPANTS Chief Executive Officer — Dr. Marianne De BackerChief Medical Officer — Dr. Mark D. EisnerChief Financial Officer — Jason O’ByrneConsulting Cli... Full story

Yahoo Finance • 5 months ago

Vir Biotechnology issues license to Norgine to market hepatitis D candidate

[Hepatitis Concept] eenevski/iStock via Getty Images * Vir Biotechnology (VIR [https://seekingalpha.com/symbol/VIR]) has granted Norgine Pharma UK an exclusive license to market its experimental chronic hepatitis d treatment, a combinat... Full story

Yahoo Finance • 6 months ago

Is Alnylam Pharmaceuticals a Millionaire Maker?

Key Points Alnylam has been a big winner for investors since its IPO in 2004. The drugmaker's future looks promising. Whether or not Alnylam is a millionaire maker, the stock should be able to generate exceptional long-term returns.10 sto... Full story

Yahoo Finance • 6 months ago

Ability Biotherapeutics Expands its Scientific Advisory Board with the Appointment of Dr. John Burke and Dr. Alan Korman

MONTREAL, November 19, 2025--(BUSINESS WIRE)--Ability Biotherapeutics, a next-generation biotherapeutics company developing logic-gated antibodies for safer and more effective immunotherapies, announces the appointment of Dr. John Burke an... Full story

Yahoo Finance • 7 months ago

Vir Biotechnology outlines accelerated hepatitis delta milestones and cash runway into mid-2027 as ECLIPSE 1 completes enrollment early

Earnings Call Insights: Vir Biotechnology, Inc. (VIR) Q3 2025 MANAGEMENT VIEW * CEO Marianne De Backer highlighted the completion of enrollment in ECLIPSE 1, Vir’s first registrational Phase III study for hepatitis delta, ahead of inte... Full story

Yahoo Finance • 9 months ago

Stocks making the biggest moves midday: Alphabet, Bruker, Sprinklr, Dollar Tree & more

Check out the companies making the biggest moves midday: Bruker – The diagnostics solutions stock dropped more than 11% after it announce the sale of $600 million in convertible stocks. The decline puts Bruker on pace for its biggest one-d... Full story

Yahoo Finance • 9 months ago

Stocks making the biggest moves premarket: Alphabet, Macy's, Dollar Tree, Six Flags and more

Check out the companies making headlines in premarket trading. Alphabet — The parent of Google and YouTube jumped more than 6% after a federal judge ruled that Alphabet can keep its Chrome browser. But Google won't be able to sign exclusiv... Full story